1、Issue BriefMay 2024China and Medical AIImplications of Big Biodata for the BioeconomyAuthorsCaroline SchuergerVikram VenkatramKatherine QuinnCenter for Security and Emerging Technology|1 Executive Summary Medical artificial intelligence is an area of emerging technology that leverages biomedical adv

2、ances and AI to power new discoveries for human health.Medical AI can help researchers discover new medicines,understand complex causes of disease,and predict how patients will respond to therapies.As these applications improve public health outcomes,they also contribute to the growing global bioeco

3、nomy.Countries that strategically prioritize medical AI could enjoy a competitive economic advantage and set global standards and norms for future developments.Medical AI leadership depends on access to large repositories of biological data,or biodata.Biodata can include information collected from i

4、ndividuals,such as their unique genetic sequences or medical records.Researchers and developers who have access to large amounts of high-quality biodata are at an advantage,as this resource is a limiting factor for medical AI advancement.China has created a comprehensive national strategy to support

5、 medical AI development and advance its goals for bioeconomy leadership.This report examines Chinas stated goals for medical AI,which range from the collection and protection of vast amounts of biodata,to facilitating research and development,to supporting medical AI commercialization.We find that:C

6、hina has access to publicly-available biodata from around the world,while its domestic datasets are closed off to other countries.Access to more biodata facilitates more powerful medical AI applications.Medical AI research publications from both China and the United States are on the rise.The United